Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
SMC (540/09)
01/12/2009
Indication
Chronic Lymphocytic Leukaemia (CLL)
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
100mg and 500mg concentrate for solution for infusion
Comments
December 2009 - Added to the Additional List, for Specialist Use only.